哒嗪类化合物作为用于治疗帕金森病或额颞叶痴呆的NLRP3抑制剂
Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Nov 7;15(12):2083-2084. doi: 10.1021/acsmedchemlett.4c00523. eCollection 2024 Dec 12.
Abstract
Provided herein are novel pyridazine compounds as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating Parkinson's disease or frontotemporal dementia, and processes for preparing such compounds.
摘要
本文提供了作为NLRP3抑制剂的新型哒嗪化合物、药物组合物、此类化合物在治疗帕金森病或额颞叶痴呆中的用途以及制备此类化合物的方法。
相似文献
1
Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.
ACS Med Chem Lett. 2024 Nov 7;15(12):2083-2084. doi: 10.1021/acsmedchemlett.4c00523. eCollection 2024 Dec 12.
2
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
3
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
4
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
5
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
6
Exploring the therapeutic potential of NLRP3 inhibitors in Parkinson's Disease: a systematic review of in-vivo studies.
Inflammopharmacology. 2025 Apr 21. doi: 10.1007/s10787-025-01733-x.
7
Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease.
ACS Med Chem Lett. 2023 Aug 1;14(8):1047-1048. doi: 10.1021/acsmedchemlett.3c00311. eCollection 2023 Aug 10.
8
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
9
Novel Compounds as CDK2 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
10
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
本文引用的文献
1
Role of NLRP3 inflammasome in central nervous system diseases.
Cell Biosci. 2024 Jun 7;14(1):75. doi: 10.1186/s13578-024-01256-y.
2
Role of NLRP3 in Parkinson's disease: Specific activation especially in dopaminergic neurons.
Heliyon. 2024 Mar 28;10(7):e28838. doi: 10.1016/j.heliyon.2024.e28838. eCollection 2024 Apr 15.
3
NLRP3 inflammasome signalling in Alzheimer's disease.
Neuropharmacology. 2024 Jul 1;252:109941. doi: 10.1016/j.neuropharm.2024.109941. Epub 2024 Mar 31.
4
Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action.
Biomed Pharmacother. 2024 Apr;173:116373. doi: 10.1016/j.biopha.2024.116373. Epub 2024 Mar 4.
5
Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue.
Mol Neurobiol. 2024 Sep;61(9):7092-7108. doi: 10.1007/s12035-024-04003-z. Epub 2024 Feb 17.
6
Molecular crosstalk between circadian clock and NLRP3 inflammasome signaling in Parkinson's disease.
Heliyon. 2024 Jan 14;10(2):e24752. doi: 10.1016/j.heliyon.2024.e24752. eCollection 2024 Jan 30.
Zotero 插件